Chugai Pharmaceutical Co. Ltd (CHGCF) 32.3500 $CHGCF
Gastric Cancer - Pipeline Review, H2 2015 Featuring Over 100 Companies
M2 - Mon Oct 05, 5:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lhb64g/gastric_cancer) has announced the addition of the "Gastric Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Gastric Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastric Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - 30 of the 100 Companies - AB Science SA - AbbVie Inc. - AbGenomics International, Inc. - Advaxis, Inc. - Advenchen Laboratories, LLC - AlphaVax, Inc. - Ambrx, Inc. - Amgen Inc. - Aslan Pharmaceuticals Pte. Ltd. - Astellas Pharma Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Azaya Therapeutics Incorporated - Basilea Pharmaceutica AG - Bayer AG - BioMarin Pharmaceutical Inc. - Biotecnol, Inc. - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - cCAM Biotherapeutics Ltd. - Celgene Corporation - Celldex Therapeutics, Inc. - Cellectar Biosciences, Inc. - Celltrion, Inc. - Celon Pharma Sp. z o.o. - Cerulean Pharma, Inc. - Chipscreen Biosciences Ltd - Chugai Pharmaceutical Co., Ltd. - Curaxys, S.L. For more information visit http://www.researchandmarkets.com/research/lh...ric_cancer
CLRB: 2.01 (+0.03), ADXS: 11.07 (+0.83), BMRN: 102.69 (+1.97), CERU: 3.65 (+0.07), AMBX: (), CLDX: 12.80 (+1.06), AMGN: 149.59 (-0.31), BMY: 61.44 (+0.93), AZN: 32.23 (-0.16), AVEO: 1.27 (+0.05), ABBV: 55.64 (-0.40), CELGZ: 1.74 (+0.04)
Company Profile for Chugai Pharmaceutical Co., Ltd.
Business Wire - Thu Oct 01, 7:10PM CDT
Chugai Pharmaceutical (TOKYO:4519) is one of Japan's leading research-based pharmaceutical companies with strengths in biotechnology products. Chugai, based in Tokyo, specializes in prescription pharmaceuticals and is listed on the 1st section of the Tokyo Stock Exchange. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which may satisfy the unmet medical needs, mainly focusing on the oncology area. In Japan, Chugai's research facilities in Gotemba and Kamakura are collaborating to develop new pharmaceuticals and laboratories in Ukima are conducting research for technology development for industrial production. Overseas, Chugai Pharmabody Research based in Singapore is engaged in research focusing on the generation of novel antibody drugs by utilizing Chugai's proprietary innovative antibody engineering technologies. Chugai Pharma USA and Chugai Pharma Europe are engaged in clinical development activities in the United States and Europe. The consolidated revenue in 2014 of Chugai totaled 461.1 billion yen and the operating income was 77.3 billion yen (IFRS Core basis).
Launch of Netupitant-Palonosetron Fixed Combination (Akynzeo(R)) in the UK by Chugai Pharma UK Ltd.
Business Wire - Thu Sep 10, 1:00AM CDT
Chugai Pharmaceutical Co., Ltd. [Head Office: Chuo-ku, Tokyo; Chairman and CEO: Osamu Nagayama] (Chugai) (TOKYO:4519) and a wholly owned subsidiary of Chugai, Chugai Pharma Marketing Ltd. [Head Office: London, the UK; Managing Director: John Halls] (CPM) and Helsinn Group [Head Office: Lugano, Switzerland; CEO: Riccardo Braglia], the Swiss Group focused on building quality cancer care, today announced that Akynzeo(R), an oral fixed-dose combination of netupitant (highly-selective NK1 receptor antagonist) and palonosetron (clinically and pharmacologically distinct 5-HT3 receptor antagonist) indicated for the prevention of chemotherapy-induced nausea and vomiting (CINV), has been launched by a wholly owned subsidiary of CPM, Chugai Pharma UK Ltd. [Head Office: London, the UK; Managing Director: Ruth Currie] (CPU), in the UK as from September 1, 2015. CPM has been granted the exclusive right of Akynzeo for sales and marketing from Helsinn Healthcare S.A.
Chugai's ALK Inhibitor "Alectinib," New Drug Application Submitted for ALK Positive Advanced Non-Small Cell Lung Cancer in the United States
Business Wire - Wed Sep 09, 12:00AM CDT
Chugai Pharmaceutical Co., Ltd. [Main Office: Chuo-ku, Tokyo. Chairman & CEO: Osamu Nagayama] (Chugai) (TOKYO:4519) and F. Hoffmann-La Roche Ltd. [Head Office: Basel, Switzerland. CEO: Severin Schwan] (Roche) announced today that Genentech, Inc. [Head Office: California, U.S., CEO: Ian T. Clark], a member of the Roche Group, has filed a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) and the FDA has accepted the NDA, for ALK (Anaplastic Lymphoma Kinase) inhibitor "alectinib hydrochloride" (alectinib) for the treatment of patient with ALK positive advanced non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib in September.
Chugai's Bispecific Antibody "ACE910" for the Treatment of Hemophilia A Designated as a Breakthrough Therapy by the US FDA
Business Wire - Fri Sep 04, 12:00AM CDT
Chugai Pharmaceutical Co., Ltd. [Head Office: Chuo-ku, Tokyo; Chairman & CEO: Osamu Nagayama] (hereafter, "Chugai"
announced today that the US Food and Drug Administration (FDA) has granted the Breakthrough Therapy Designation to "ACE910," for the prophylactic treatment of people who are 12 years or older with hemophilia A with factor VIII inhibitors.
Osteoporosis Pipeline Review, H1 2015 - Reviews key players involved in the therapeutics development for Osteoporosis
M2 - Mon Aug 17, 8:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7r4gzx/osteoporosis) has announced the addition of the "Osteoporosis - Pipeline Review, H1 2015" report to their offering. Summary This report provides comprehensive information on the therapeutic development for Osteoporosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoporosis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Scope - The report provides a snapshot of the global therapeutic landscape of Osteoporosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report summarizes all the dormant and discontinued pipeline projects - A review of the Osteoporosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned - Abiogen Pharma S.p.A. - Ablynx NV - Alethia Biotherapeutics Inc. - Alize Pharma SAS - Alkem Laboratories Ltd. - Amgen Inc. - Amura Holdings Limited - Arcarios BV - Astellas Pharma Inc. - Bone Medical Limited - Bone Therapeutics SA - Caladrius Biosciences, Inc. - Chronos Therapeutics Limited - Chugai Pharmaceutical Co., Ltd. - Corium International, Inc. - Critical Pharmaceuticals Limited - Daiichi Sankyo Company, Limited - ElexoPharm GmbH - Eli Lilly and Company - EndoCeutics, Inc. - Ensoltek Co., Ltd. - Enzo Biochem, Inc. - F. Hoffmann-La Roche Ltd. - Galapagos NV - Glide Pharmaceutical Technologies Limited - Hanmi Pharmaceuticals, Co. Ltd. - Haoma Medica Ltd. - IMMD Inc. - Immunovo BV - Inbiopro Solutions Pvt. Ltd. - Kaken Pharmaceutical Co., Ltd. - Kolltan Pharmaceuticals, Inc. - Lead Discovery Center GmbH For more information visit http://www.researchandmarkets.com/research/7r...teoporosis
AMGN: 149.59 (-0.31), LLY: 86.14 (+2.37), CLBS: 1.38 (unch), GLPG: 44.35 (+0.81), CORI: 8.87 (+0.23), ENZ: 3.75 (+0.04)
Neuroblastoma Pipeline Review, H1 2015 - Reviews Key Players Involved in the Therapeutics Development for Neuroblastoma
M2 - Mon Aug 17, 8:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9kbwkd/neuroblastoma) has announced the addition of the "Neuroblastoma - Pipeline Review, H1 2015" report to their offering. Summary This, Neuroblastoma - Pipeline Review, H1 2015', provides an overview of the Neuroblastoma's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Neuroblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuroblastoma and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Scope - The report provides a snapshot of the global therapeutic landscape of Neuroblastoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report summarizes all the dormant and discontinued pipeline projects - A review of the Neuroblastoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned - Ability Pharma, SL - Acetylon Pharmaceuticals, Inc. - Advanced Accelerator Applications SA - Aeterna Zentaris Inc. - Ampio Pharmaceuticals, Inc. - APEIRON Biologics AG - Aptose Biosciences Inc. - AstraZeneca Plc - Bellicum Pharmaceuticals, Inc. - Bexion Pharmaceuticals, LLC. - BioLineRx, Ltd. - Bionucleon Srl - Cebiotex, S.L. - Celgene Corporation - Chugai Pharmaceutical Co., Ltd. - Cleveland BioLabs, Inc. - CureFAKtor Pharmaceuticals, LLC - DEKK-TEC, Inc. - Errant Gene Therapeutics, LLC - F. Hoffmann-La Roche Ltd. - Gamida Cell Ltd. - Ignyta, Inc. - Juno Therapeutics Inc. - Lindis Biotech GmbH - MabVax Therapeutics Holdings, Inc. - Merck & Co., Inc. - Merrimack Pharmaceuticals, Inc. - Netris Pharma S.A.S. - Novartis AG - Novogen Limited - Pono Pharma - Progenics Pharmaceuticals, Inc. - Recombio S.L For more information visit http://www.researchandmarkets.com/research/9k...roblastoma
AMPE: 3.04 (+0.05), AAAP: (), MACK: 9.60 (+0.17), PGNX: 5.77 (+0.26), APTO: 4.14 (+0.03), BLCM: 14.65 (+0.39), RXDX: 10.36 (-0.03), AZN: 32.23 (-0.16), MRK: 50.95 (-0.07), JUNO: 48.64 (+0.84), CBLI: 4.53 (+0.07), NVS: 91.90 (-0.71), CELGZ: 1.74 (+0.04)
Hypoparathyroidism Therapeutics Pipeline Review, H1 2015 - 3 Companies & 5 Drug Profiles
M2 - Tue Jul 28, 9:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xgk54k/hypoparathyroidism) has announced the addition of the "Hypoparathyroidism - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hypoparathyroidism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypoparathyroidism and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Chugai Pharmaceutical Co., Ltd. - Rhein-Minapharm Biogenetics SAE - Shire Plc Drug Profiles - Eu-232 - parathyroid hormone (recombinant) - PCO-371 - Recombinant Protein to Agonize PTH-R for Hypoparathyroidism - teriparatide For more information visit http://www.researchandmarkets.com/research/xg...thyroidism
SHPG: 200.90 (-1.85)
Sector's Smaller Players Show The Way
EP Vantage - at Seeking Alpha - Sat Jul 04, 11:28AM CDT
With the Nasdaq biotech index proving remarkably resilient to sector-specific and macroeconomic problems alike, smart investors will continue to keep an eye out for signs of panic as a leading indicator of an overall collapse of sentiment. Nothing...
SGYP: 6.32 (+0.18), BIIB: 269.16 (-10.72), ZIOP: 10.92 (+0.32), BMRN: 102.69 (+1.97), PCYC: 261.25 (+1.70), CLDN: 1.12 (+0.03), HSP: 89.95 (-0.01), HRTX: 25.72 (-0.93), ANTH: 6.12 (+0.12), SHPG: 200.90 (-1.85), CLLS: 26.61 (-0.16), RTRX: 20.22 (+1.07), JUNO: 48.64 (+0.84), ABBV: 55.64 (-0.40), AAVL: 8.48 (+0.01), SNY: 48.75 (+0.03), PFE: 33.24 (+0.15), SLXP: 172.96 (+0.15), GSK: 40.22 (+0.06), CELG: 117.38 (-0.59), ISIS: 43.24 (+0.86), TARO: 148.37 (-0.08), PBYI: 79.41 (+3.89), NVS: 91.90 (-0.71)
Neuromyelitis Optica (Devic's Syndrome) Pipeline Report 2015 - 9 Companies & 10 Drug Profiles
M2 - Thu May 21, 9:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/34rhhd/neuromyelitis) has announced the addition of the "Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Neuromyelitis Optica (Devic's Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuromyelitis Optica (Devic's Syndrome) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acorda Therapeutics, Inc. - Alexion Pharmaceuticals, Inc. - Chugai Pharmaceutical Co., Ltd. - HanAll Biopharma Co., Ltd. - MedImmune, LLC - Opexa Therapeutics, Inc. - Shenzhen Beike Biotechnology Co., Ltd. - Shire Plc - Takeda Pharmaceutical Company Limited Drug Profiles - C1 esterase inhibitor (human) - dalfampridine ER - Dendritic Cell Therapy for Central Nervous System Disorders - eculizumab - HL-161 - immune globulin (human) - MEDI-551 - NU-21101 NU-21502 - OPX-212 - SA-237 For more information visit http://www.researchandmarkets.com/research/34...romyelitis
OPXA: 3.20 (-0.08), SHPG: 200.90 (-1.85), ALXN: 161.08 (-3.23), ACOR: 29.89 (-0.22)
Global Hepatitis C Pipeline Report 2015 - 103 Companies & 251 Drug Profiles
M2 - Wed May 20, 4:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/96rn9k/hepatitis_c) has announced the addition of the "Hepatitis C - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatitis C, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis C and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 30 of the 100 Companies - 3-V Biosciences, Inc. - AbbVie Inc. - Achillion Pharmaceuticals, Inc. - Adaptimmune Limited - AiCuris GmbH & Co. KG - AIMM Therapeutics B.V. - Akshaya Bio Inc. - Alnylam Pharmaceuticals, Inc. - Altor BioScience Corporation - Amarna Therapeutics B.V. - American Gene Technologies International Inc. - Anacor Pharmaceuticals, Inc. - ARA Healthcare Pvt. Ltd. - Arrowhead Research Corporation - Ascendis Pharma A/S - Astex Pharmaceuticals, Inc. - Biogenomics Limited - BioLineRx, Ltd. - Bionor Pharma ASA - Biotest AG - Biotron Limited - Bolder Biotechnology, Inc. - Bristol-Myers Squibb Company - Celgene Corporation - Chiasma, Inc. - Chugai Pharmaceutical Co., Ltd. - Cocrystal Pharma, Inc. - Conatus Pharmaceuticals Inc. - Crucell N.V. - Debiopharm International S.A. For more information visit http://www.researchandmarkets.com/research/96...epatitis_c
ASND: 17.24 (+0.05), ARWR: 5.89 (+0.13), ACHN: 7.57 (-0.10), CNAT: 4.21 (-0.06), ANAC: 115.06 (+2.13), ABBV: 55.64 (-0.40), BMY: 61.44 (+0.93), CELGZ: 1.74 (+0.04)
Global Gastric Cancer Pipeline Report 2015
M2 - Thu May 14, 5:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/527p3s/gastric_cancer) has announced the addition of the "Gastric Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Gastric Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastric Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Gastric Cancer Overview - Therapeutics Development - Gastric Cancer - Therapeutics under Development by Companies - Gastric Cancer - Therapeutics under Investigation by Universities/Institutes - Gastric Cancer - Pipeline Products Glance - Gastric Cancer - Products under Development by Companies - Gastric Cancer - Products under Investigation by Universities/Institutes - Gastric Cancer - Companies Involved in Therapeutics Development - Gastric Cancer - Therapeutics Assessment - Drug Profiles - Gastric Cancer - Recent Pipeline Updates - Gastric Cancer - Dormant Projects - Gastric Cancer - Discontinued Products - Gastric Cancer - Product Development Milestones - Appendix Companies Mentioned: Partial List - AB Science - Chipscreen Biosciences Ltd - Chugai Pharmaceutical Co., Ltd. - Covagen AG - DAE HWA Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - Galena Biopharma, Inc. - Genentech, Inc. - GlaxoSmithKline plc - GlycoNex Inc. - Glycotope GmbH - ISU ABXIS Co.,Ltd. - Jiangsu Hengrui Medicine Co., Ltd. - Jiangsu Kanion Pharmaceutical Co., Ltd. - Kadmon Corporation, LLC - Millennium Pharmaceuticals, Inc. - Molecular Targeting Technologies, Inc. - MSM Protein Technologies, Inc. - NanoCarrier Co., Ltd. - NeoPharm Co., Ltd. - Novartis AG - Regulon Inc. - Rexahn Pharmaceuticals, Inc. - Richter Gedeon Nyrt. - Sanofi - Sareum Holdings plc - SentoClone International AB - Sequella, Inc. - Zymeworks Inc. For more information visit http://www.researchandmarkets.com/research/52...ric_cancer
RNN: 0.51 (+0.02), GALE: 1.74 (+0.01), GSK: 40.22 (+0.06), NVS: 91.90 (-0.71)
Selection of Board Member Candidates
M2 - Thu Apr 30, 5:27AM CDT
The candidates for election to the position of Member of the Board are as follows.Kazuo Hirai Representative Corporate Executive Officer, President and CEO Kenichiro Yoshida Representative Corporate Executive Officer, Executive Deputy President and CFO Kanemitsu Anraku(*) Director, Mizuho Financial Group, Inc. Osamu Nagayama(*) Representative Director, Chairman and Chief Executive Officer, Chugai Pharmaceutical Co., Ltd. Takaaki Nimura(*) Certified Public Accountant Eikoh Harada(*) Representative Director, Chairman and CEO, Benesse Holdings, Inc.
MFG: 3.93 (-0.04)
Global Dermatitis Pipeline Review 2015
M2 - Mon Apr 27, 4:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7sjwj3/dermatitis) has announced the addition of the "Dermatitis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dermatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dermatitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Dermatitis Overview - Therapeutics Development - Dermatitis - Therapeutics under Development by Companies - Dermatitis - Therapeutics under Investigation by Universities/Institutes - Dermatitis - Pipeline Products Glance - Dermatitis - Products under Development by Companies - Dermatitis - Products under Investigation by Universities/Institutes - Dermatitis - Companies Involved in Therapeutics Development - Dermatitis - Therapeutics Assessment - Drug Profiles - Dermatitis - Recent Pipeline Updates - Dermatitis - Dormant Projects - Dermatitis - Discontinued Products - Dermatitis - Product Development Milestones - Appendix Companies Mentioned - Partial List - AlbireoPharma - Amorepacific Corporation - Anacor Pharmaceuticals, Inc. - AnaMar AB - AnaptysBio, Inc. - AnGes MG, Inc. - Aquinox Pharmaceuticals Inc. - arGEN-X BV - Biomar Microbial Technologies - Blueberry Therapeutics Ltd - Brickell Biotech, Inc. - Bristol-Myers Squibb Company - Celgene Corporation - Celsus Therapeutics Plc - ChemoCentryx, Inc. - China Biologic Products, Inc. - ChironWells GmbH - Chugai Pharmaceutical Co., Ltd. - Circassia Pharmaceuticals plc - Convoy Therapeutics, Inc. - Creabilis SA - Daiichi Sankyo Company, Limited - Dermira Inc. - Eisai Co., Ltd. - EpiPharm AG - F. Hoffmann-La Roche Ltd. - FAES Farma SA - Foamix Pharmaceuticals Ltd. - Fountain Biopharma Inc. - GlaxoSmithKline plc For more information visit http://www.researchandmarkets.com/research/7sjwj3/dermatitis
AQXP: 12.90 (+0.11), FOMX: 6.84 (+0.17), GSK: 40.22 (+0.06), BMY: 61.44 (+0.93), CBPO: 97.22 (+2.50), DERM: 26.14 (+0.81), CCXI: 6.45 (+0.02), ANAC: 115.06 (+2.13), CLTX: 36.01 (+16.34), CELGZ: 1.74 (+0.04)
Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 21, 10:31AM CDT
The report "Dermatitis - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Dermatitis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/dermatitis-p...eport.html .
VTAE: 13.00 (+0.10), FOMX: 6.84 (+0.17), PVCT: 0.56 (unch), JNJ: 95.37 (+0.29), DERM: 26.14 (+0.81), ANAC: 115.06 (+2.13), XNCR: 12.28 (-0.13), REGN: 503.92 (+12.71), AQXP: 12.90 (+0.11), BMY: 61.44 (+0.93), GSK: 40.22 (+0.06), VRX.TO: 227.56 (+4.67), CBPO: 97.22 (+2.50), MRK: 50.95 (-0.07), CCXI: 6.45 (+0.02), CLTX: 36.01 (+16.34), CELGZ: 1.74 (+0.04), NVS: 91.90 (-0.71)
Why Investors Shouldn't Worry About Explosive New Drug Pricing: Maxim's Jason Kolbert
Life Sciences Report - Seeking Alpha - Thu Apr 09, 4:59PM CDT
It's the daring Phase 2-stage molecules of today that will bring patients a generation of biotech drugs that could cure certain deadly diseases tomorrow. The candidates that succeed will also energize the portfolios of investors who have exercised...
PSTI: 1.84 (+0.06), NBS: 2.25 (-0.09), OSIR: 16.97 (+0.31), BCLI: 2.87 (+0.13), MDVN: 41.26 (+2.03), INO: 6.16 (+0.20), CYTX: 0.42 (+0.02), STEM: 0.44 (+0.04), JUNO: 48.64 (+0.84), ATHX: 1.14 (-0.01), CUR: 1.33 (+0.03), BLUE: 88.80 (+0.30), VRTX: 110.00 (+0.97), AMGN: 149.59 (-0.31), KERX: 4.25 (+0.23), OMER: 12.66 (+0.58), KITE: 63.33 (+0.26), GILD: 100.65 (-0.16), MRK: 50.95 (-0.07), TEVA: 58.96 (-0.28)
Will Stem Cell Profits Measure Up?: NxR Biotechnologies' Alain Vertès
Life Sciences Report - Seeking Alpha - Thu Mar 19, 6:10AM CDT
It makes no sense to look at stem cell companies differently from drug or biologics companies. The technology may be different, but the diseases they seek to treat are the same. In fact, cell therapies may ultimately be more useful and more curative...
PFE: 33.24 (+0.15), ATHX: 1.14 (-0.01)
Chugai licenses ISPRI/OptiMatrix platform from EpiVax for de-risking biologics
PR Newswire - Thu Oct 30, 10:17AM CDT
Chugai Pharmaceutical Co., Ltd. (Chugai), signed an agreement with Rhode Island-based biotechnology company, EpiVax, Inc., to incorporate EpiVax's ISPRI immunogenicity screening and deimmunization technology into Chugai's drug development toolbox. Chugai is widely regarded as one of the most cutting edge biopharmaceutical companies in Japan. Researchers at Chugai will be utilizing the cloud-based in silico "Interactive Protein Screening and Reengineering Interface" (ISPRI) in conjunction with OptiMatrix, a tool for deimmunizing biologics, to screen and re-engineer therapeutic proteins for potential immunogenicity and deimmunize immune-dominant epitopes, known as clusters.
Gastric Cancer - Pipeline Review, H2 2015 Featuring Over 100 Companies
M2 - Mon Oct 05, 5:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lhb64g/gastric_cancer) has announced the addition of the "Gastric Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Gastric Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastric Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - 30 of the 100 Companies - AB Science SA - AbbVie Inc. - AbGenomics International, Inc. - Advaxis, Inc. - Advenchen Laboratories, LLC - AlphaVax, Inc. - Ambrx, Inc. - Amgen Inc. - Aslan Pharmaceuticals Pte. Ltd. - Astellas Pharma Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Azaya Therapeutics Incorporated - Basilea Pharmaceutica AG - Bayer AG - BioMarin Pharmaceutical Inc. - Biotecnol, Inc. - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - cCAM Biotherapeutics Ltd. - Celgene Corporation - Celldex Therapeutics, Inc. - Cellectar Biosciences, Inc. - Celltrion, Inc. - Celon Pharma Sp. z o.o. - Cerulean Pharma, Inc. - Chipscreen Biosciences Ltd - Chugai Pharmaceutical Co., Ltd. - Curaxys, S.L. For more information visit http://www.researchandmarkets.com/research/lh...ric_cancer
CLRB: 2.01 (+0.03), ADXS: 11.07 (+0.83), BMRN: 102.69 (+1.97), CERU: 3.65 (+0.07), AMBX: (), CLDX: 12.80 (+1.06), AMGN: 149.59 (-0.31), BMY: 61.44 (+0.93), AZN: 32.23 (-0.16), AVEO: 1.27 (+0.05), ABBV: 55.64 (-0.40), CELGZ: 1.74 (+0.04)
Company Profile for Chugai Pharmaceutical Co., Ltd.
Business Wire - Thu Oct 01, 7:10PM CDT
Chugai Pharmaceutical (TOKYO:4519) is one of Japan's leading research-based pharmaceutical companies with strengths in biotechnology products. Chugai, based in Tokyo, specializes in prescription pharmaceuticals and is listed on the 1st section of the Tokyo Stock Exchange. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which may satisfy the unmet medical needs, mainly focusing on the oncology area. In Japan, Chugai's research facilities in Gotemba and Kamakura are collaborating to develop new pharmaceuticals and laboratories in Ukima are conducting research for technology development for industrial production. Overseas, Chugai Pharmabody Research based in Singapore is engaged in research focusing on the generation of novel antibody drugs by utilizing Chugai's proprietary innovative antibody engineering technologies. Chugai Pharma USA and Chugai Pharma Europe are engaged in clinical development activities in the United States and Europe. The consolidated revenue in 2014 of Chugai totaled 461.1 billion yen and the operating income was 77.3 billion yen (IFRS Core basis).
Launch of Netupitant-Palonosetron Fixed Combination (Akynzeo(R)) in the UK by Chugai Pharma UK Ltd.
Business Wire - Thu Sep 10, 1:00AM CDT
Chugai Pharmaceutical Co., Ltd. [Head Office: Chuo-ku, Tokyo; Chairman and CEO: Osamu Nagayama] (Chugai) (TOKYO:4519) and a wholly owned subsidiary of Chugai, Chugai Pharma Marketing Ltd. [Head Office: London, the UK; Managing Director: John Halls] (CPM) and Helsinn Group [Head Office: Lugano, Switzerland; CEO: Riccardo Braglia], the Swiss Group focused on building quality cancer care, today announced that Akynzeo(R), an oral fixed-dose combination of netupitant (highly-selective NK1 receptor antagonist) and palonosetron (clinically and pharmacologically distinct 5-HT3 receptor antagonist) indicated for the prevention of chemotherapy-induced nausea and vomiting (CINV), has been launched by a wholly owned subsidiary of CPM, Chugai Pharma UK Ltd. [Head Office: London, the UK; Managing Director: Ruth Currie] (CPU), in the UK as from September 1, 2015. CPM has been granted the exclusive right of Akynzeo for sales and marketing from Helsinn Healthcare S.A.
Chugai's ALK Inhibitor "Alectinib," New Drug Application Submitted for ALK Positive Advanced Non-Small Cell Lung Cancer in the United States
Business Wire - Wed Sep 09, 12:00AM CDT
Chugai Pharmaceutical Co., Ltd. [Main Office: Chuo-ku, Tokyo. Chairman & CEO: Osamu Nagayama] (Chugai) (TOKYO:4519) and F. Hoffmann-La Roche Ltd. [Head Office: Basel, Switzerland. CEO: Severin Schwan] (Roche) announced today that Genentech, Inc. [Head Office: California, U.S., CEO: Ian T. Clark], a member of the Roche Group, has filed a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) and the FDA has accepted the NDA, for ALK (Anaplastic Lymphoma Kinase) inhibitor "alectinib hydrochloride" (alectinib) for the treatment of patient with ALK positive advanced non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib in September.
Chugai's Bispecific Antibody "ACE910" for the Treatment of Hemophilia A Designated as a Breakthrough Therapy by the US FDA
Business Wire - Fri Sep 04, 12:00AM CDT
Chugai Pharmaceutical Co., Ltd. [Head Office: Chuo-ku, Tokyo; Chairman & CEO: Osamu Nagayama] (hereafter, "Chugai"
announced today that the US Food and Drug Administration (FDA) has granted the Breakthrough Therapy Designation to "ACE910," for the prophylactic treatment of people who are 12 years or older with hemophilia A with factor VIII inhibitors. Osteoporosis Pipeline Review, H1 2015 - Reviews key players involved in the therapeutics development for Osteoporosis
M2 - Mon Aug 17, 8:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7r4gzx/osteoporosis) has announced the addition of the "Osteoporosis - Pipeline Review, H1 2015" report to their offering. Summary This report provides comprehensive information on the therapeutic development for Osteoporosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoporosis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Scope - The report provides a snapshot of the global therapeutic landscape of Osteoporosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report summarizes all the dormant and discontinued pipeline projects - A review of the Osteoporosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned - Abiogen Pharma S.p.A. - Ablynx NV - Alethia Biotherapeutics Inc. - Alize Pharma SAS - Alkem Laboratories Ltd. - Amgen Inc. - Amura Holdings Limited - Arcarios BV - Astellas Pharma Inc. - Bone Medical Limited - Bone Therapeutics SA - Caladrius Biosciences, Inc. - Chronos Therapeutics Limited - Chugai Pharmaceutical Co., Ltd. - Corium International, Inc. - Critical Pharmaceuticals Limited - Daiichi Sankyo Company, Limited - ElexoPharm GmbH - Eli Lilly and Company - EndoCeutics, Inc. - Ensoltek Co., Ltd. - Enzo Biochem, Inc. - F. Hoffmann-La Roche Ltd. - Galapagos NV - Glide Pharmaceutical Technologies Limited - Hanmi Pharmaceuticals, Co. Ltd. - Haoma Medica Ltd. - IMMD Inc. - Immunovo BV - Inbiopro Solutions Pvt. Ltd. - Kaken Pharmaceutical Co., Ltd. - Kolltan Pharmaceuticals, Inc. - Lead Discovery Center GmbH For more information visit http://www.researchandmarkets.com/research/7r...teoporosis
AMGN: 149.59 (-0.31), LLY: 86.14 (+2.37), CLBS: 1.38 (unch), GLPG: 44.35 (+0.81), CORI: 8.87 (+0.23), ENZ: 3.75 (+0.04)
Neuroblastoma Pipeline Review, H1 2015 - Reviews Key Players Involved in the Therapeutics Development for Neuroblastoma
M2 - Mon Aug 17, 8:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9kbwkd/neuroblastoma) has announced the addition of the "Neuroblastoma - Pipeline Review, H1 2015" report to their offering. Summary This, Neuroblastoma - Pipeline Review, H1 2015', provides an overview of the Neuroblastoma's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Neuroblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuroblastoma and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Scope - The report provides a snapshot of the global therapeutic landscape of Neuroblastoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report summarizes all the dormant and discontinued pipeline projects - A review of the Neuroblastoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned - Ability Pharma, SL - Acetylon Pharmaceuticals, Inc. - Advanced Accelerator Applications SA - Aeterna Zentaris Inc. - Ampio Pharmaceuticals, Inc. - APEIRON Biologics AG - Aptose Biosciences Inc. - AstraZeneca Plc - Bellicum Pharmaceuticals, Inc. - Bexion Pharmaceuticals, LLC. - BioLineRx, Ltd. - Bionucleon Srl - Cebiotex, S.L. - Celgene Corporation - Chugai Pharmaceutical Co., Ltd. - Cleveland BioLabs, Inc. - CureFAKtor Pharmaceuticals, LLC - DEKK-TEC, Inc. - Errant Gene Therapeutics, LLC - F. Hoffmann-La Roche Ltd. - Gamida Cell Ltd. - Ignyta, Inc. - Juno Therapeutics Inc. - Lindis Biotech GmbH - MabVax Therapeutics Holdings, Inc. - Merck & Co., Inc. - Merrimack Pharmaceuticals, Inc. - Netris Pharma S.A.S. - Novartis AG - Novogen Limited - Pono Pharma - Progenics Pharmaceuticals, Inc. - Recombio S.L For more information visit http://www.researchandmarkets.com/research/9k...roblastoma
AMPE: 3.04 (+0.05), AAAP: (), MACK: 9.60 (+0.17), PGNX: 5.77 (+0.26), APTO: 4.14 (+0.03), BLCM: 14.65 (+0.39), RXDX: 10.36 (-0.03), AZN: 32.23 (-0.16), MRK: 50.95 (-0.07), JUNO: 48.64 (+0.84), CBLI: 4.53 (+0.07), NVS: 91.90 (-0.71), CELGZ: 1.74 (+0.04)
Hypoparathyroidism Therapeutics Pipeline Review, H1 2015 - 3 Companies & 5 Drug Profiles
M2 - Tue Jul 28, 9:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xgk54k/hypoparathyroidism) has announced the addition of the "Hypoparathyroidism - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hypoparathyroidism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypoparathyroidism and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Chugai Pharmaceutical Co., Ltd. - Rhein-Minapharm Biogenetics SAE - Shire Plc Drug Profiles - Eu-232 - parathyroid hormone (recombinant) - PCO-371 - Recombinant Protein to Agonize PTH-R for Hypoparathyroidism - teriparatide For more information visit http://www.researchandmarkets.com/research/xg...thyroidism
SHPG: 200.90 (-1.85)
Sector's Smaller Players Show The Way
EP Vantage - at Seeking Alpha - Sat Jul 04, 11:28AM CDT
With the Nasdaq biotech index proving remarkably resilient to sector-specific and macroeconomic problems alike, smart investors will continue to keep an eye out for signs of panic as a leading indicator of an overall collapse of sentiment. Nothing...
SGYP: 6.32 (+0.18), BIIB: 269.16 (-10.72), ZIOP: 10.92 (+0.32), BMRN: 102.69 (+1.97), PCYC: 261.25 (+1.70), CLDN: 1.12 (+0.03), HSP: 89.95 (-0.01), HRTX: 25.72 (-0.93), ANTH: 6.12 (+0.12), SHPG: 200.90 (-1.85), CLLS: 26.61 (-0.16), RTRX: 20.22 (+1.07), JUNO: 48.64 (+0.84), ABBV: 55.64 (-0.40), AAVL: 8.48 (+0.01), SNY: 48.75 (+0.03), PFE: 33.24 (+0.15), SLXP: 172.96 (+0.15), GSK: 40.22 (+0.06), CELG: 117.38 (-0.59), ISIS: 43.24 (+0.86), TARO: 148.37 (-0.08), PBYI: 79.41 (+3.89), NVS: 91.90 (-0.71)
Neuromyelitis Optica (Devic's Syndrome) Pipeline Report 2015 - 9 Companies & 10 Drug Profiles
M2 - Thu May 21, 9:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/34rhhd/neuromyelitis) has announced the addition of the "Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Neuromyelitis Optica (Devic's Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuromyelitis Optica (Devic's Syndrome) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acorda Therapeutics, Inc. - Alexion Pharmaceuticals, Inc. - Chugai Pharmaceutical Co., Ltd. - HanAll Biopharma Co., Ltd. - MedImmune, LLC - Opexa Therapeutics, Inc. - Shenzhen Beike Biotechnology Co., Ltd. - Shire Plc - Takeda Pharmaceutical Company Limited Drug Profiles - C1 esterase inhibitor (human) - dalfampridine ER - Dendritic Cell Therapy for Central Nervous System Disorders - eculizumab - HL-161 - immune globulin (human) - MEDI-551 - NU-21101 NU-21502 - OPX-212 - SA-237 For more information visit http://www.researchandmarkets.com/research/34...romyelitis
OPXA: 3.20 (-0.08), SHPG: 200.90 (-1.85), ALXN: 161.08 (-3.23), ACOR: 29.89 (-0.22)
Global Hepatitis C Pipeline Report 2015 - 103 Companies & 251 Drug Profiles
M2 - Wed May 20, 4:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/96rn9k/hepatitis_c) has announced the addition of the "Hepatitis C - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatitis C, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis C and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 30 of the 100 Companies - 3-V Biosciences, Inc. - AbbVie Inc. - Achillion Pharmaceuticals, Inc. - Adaptimmune Limited - AiCuris GmbH & Co. KG - AIMM Therapeutics B.V. - Akshaya Bio Inc. - Alnylam Pharmaceuticals, Inc. - Altor BioScience Corporation - Amarna Therapeutics B.V. - American Gene Technologies International Inc. - Anacor Pharmaceuticals, Inc. - ARA Healthcare Pvt. Ltd. - Arrowhead Research Corporation - Ascendis Pharma A/S - Astex Pharmaceuticals, Inc. - Biogenomics Limited - BioLineRx, Ltd. - Bionor Pharma ASA - Biotest AG - Biotron Limited - Bolder Biotechnology, Inc. - Bristol-Myers Squibb Company - Celgene Corporation - Chiasma, Inc. - Chugai Pharmaceutical Co., Ltd. - Cocrystal Pharma, Inc. - Conatus Pharmaceuticals Inc. - Crucell N.V. - Debiopharm International S.A. For more information visit http://www.researchandmarkets.com/research/96...epatitis_c
ASND: 17.24 (+0.05), ARWR: 5.89 (+0.13), ACHN: 7.57 (-0.10), CNAT: 4.21 (-0.06), ANAC: 115.06 (+2.13), ABBV: 55.64 (-0.40), BMY: 61.44 (+0.93), CELGZ: 1.74 (+0.04)
Global Gastric Cancer Pipeline Report 2015
M2 - Thu May 14, 5:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/527p3s/gastric_cancer) has announced the addition of the "Gastric Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Gastric Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastric Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Gastric Cancer Overview - Therapeutics Development - Gastric Cancer - Therapeutics under Development by Companies - Gastric Cancer - Therapeutics under Investigation by Universities/Institutes - Gastric Cancer - Pipeline Products Glance - Gastric Cancer - Products under Development by Companies - Gastric Cancer - Products under Investigation by Universities/Institutes - Gastric Cancer - Companies Involved in Therapeutics Development - Gastric Cancer - Therapeutics Assessment - Drug Profiles - Gastric Cancer - Recent Pipeline Updates - Gastric Cancer - Dormant Projects - Gastric Cancer - Discontinued Products - Gastric Cancer - Product Development Milestones - Appendix Companies Mentioned: Partial List - AB Science - Chipscreen Biosciences Ltd - Chugai Pharmaceutical Co., Ltd. - Covagen AG - DAE HWA Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - Galena Biopharma, Inc. - Genentech, Inc. - GlaxoSmithKline plc - GlycoNex Inc. - Glycotope GmbH - ISU ABXIS Co.,Ltd. - Jiangsu Hengrui Medicine Co., Ltd. - Jiangsu Kanion Pharmaceutical Co., Ltd. - Kadmon Corporation, LLC - Millennium Pharmaceuticals, Inc. - Molecular Targeting Technologies, Inc. - MSM Protein Technologies, Inc. - NanoCarrier Co., Ltd. - NeoPharm Co., Ltd. - Novartis AG - Regulon Inc. - Rexahn Pharmaceuticals, Inc. - Richter Gedeon Nyrt. - Sanofi - Sareum Holdings plc - SentoClone International AB - Sequella, Inc. - Zymeworks Inc. For more information visit http://www.researchandmarkets.com/research/52...ric_cancer
RNN: 0.51 (+0.02), GALE: 1.74 (+0.01), GSK: 40.22 (+0.06), NVS: 91.90 (-0.71)
Selection of Board Member Candidates
M2 - Thu Apr 30, 5:27AM CDT
The candidates for election to the position of Member of the Board are as follows.Kazuo Hirai Representative Corporate Executive Officer, President and CEO Kenichiro Yoshida Representative Corporate Executive Officer, Executive Deputy President and CFO Kanemitsu Anraku(*) Director, Mizuho Financial Group, Inc. Osamu Nagayama(*) Representative Director, Chairman and Chief Executive Officer, Chugai Pharmaceutical Co., Ltd. Takaaki Nimura(*) Certified Public Accountant Eikoh Harada(*) Representative Director, Chairman and CEO, Benesse Holdings, Inc.
MFG: 3.93 (-0.04)
Global Dermatitis Pipeline Review 2015
M2 - Mon Apr 27, 4:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7sjwj3/dermatitis) has announced the addition of the "Dermatitis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dermatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dermatitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Dermatitis Overview - Therapeutics Development - Dermatitis - Therapeutics under Development by Companies - Dermatitis - Therapeutics under Investigation by Universities/Institutes - Dermatitis - Pipeline Products Glance - Dermatitis - Products under Development by Companies - Dermatitis - Products under Investigation by Universities/Institutes - Dermatitis - Companies Involved in Therapeutics Development - Dermatitis - Therapeutics Assessment - Drug Profiles - Dermatitis - Recent Pipeline Updates - Dermatitis - Dormant Projects - Dermatitis - Discontinued Products - Dermatitis - Product Development Milestones - Appendix Companies Mentioned - Partial List - AlbireoPharma - Amorepacific Corporation - Anacor Pharmaceuticals, Inc. - AnaMar AB - AnaptysBio, Inc. - AnGes MG, Inc. - Aquinox Pharmaceuticals Inc. - arGEN-X BV - Biomar Microbial Technologies - Blueberry Therapeutics Ltd - Brickell Biotech, Inc. - Bristol-Myers Squibb Company - Celgene Corporation - Celsus Therapeutics Plc - ChemoCentryx, Inc. - China Biologic Products, Inc. - ChironWells GmbH - Chugai Pharmaceutical Co., Ltd. - Circassia Pharmaceuticals plc - Convoy Therapeutics, Inc. - Creabilis SA - Daiichi Sankyo Company, Limited - Dermira Inc. - Eisai Co., Ltd. - EpiPharm AG - F. Hoffmann-La Roche Ltd. - FAES Farma SA - Foamix Pharmaceuticals Ltd. - Fountain Biopharma Inc. - GlaxoSmithKline plc For more information visit http://www.researchandmarkets.com/research/7sjwj3/dermatitis
AQXP: 12.90 (+0.11), FOMX: 6.84 (+0.17), GSK: 40.22 (+0.06), BMY: 61.44 (+0.93), CBPO: 97.22 (+2.50), DERM: 26.14 (+0.81), CCXI: 6.45 (+0.02), ANAC: 115.06 (+2.13), CLTX: 36.01 (+16.34), CELGZ: 1.74 (+0.04)
Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 21, 10:31AM CDT
The report "Dermatitis - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Dermatitis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/dermatitis-p...eport.html .
VTAE: 13.00 (+0.10), FOMX: 6.84 (+0.17), PVCT: 0.56 (unch), JNJ: 95.37 (+0.29), DERM: 26.14 (+0.81), ANAC: 115.06 (+2.13), XNCR: 12.28 (-0.13), REGN: 503.92 (+12.71), AQXP: 12.90 (+0.11), BMY: 61.44 (+0.93), GSK: 40.22 (+0.06), VRX.TO: 227.56 (+4.67), CBPO: 97.22 (+2.50), MRK: 50.95 (-0.07), CCXI: 6.45 (+0.02), CLTX: 36.01 (+16.34), CELGZ: 1.74 (+0.04), NVS: 91.90 (-0.71)
Why Investors Shouldn't Worry About Explosive New Drug Pricing: Maxim's Jason Kolbert
Life Sciences Report - Seeking Alpha - Thu Apr 09, 4:59PM CDT
It's the daring Phase 2-stage molecules of today that will bring patients a generation of biotech drugs that could cure certain deadly diseases tomorrow. The candidates that succeed will also energize the portfolios of investors who have exercised...
PSTI: 1.84 (+0.06), NBS: 2.25 (-0.09), OSIR: 16.97 (+0.31), BCLI: 2.87 (+0.13), MDVN: 41.26 (+2.03), INO: 6.16 (+0.20), CYTX: 0.42 (+0.02), STEM: 0.44 (+0.04), JUNO: 48.64 (+0.84), ATHX: 1.14 (-0.01), CUR: 1.33 (+0.03), BLUE: 88.80 (+0.30), VRTX: 110.00 (+0.97), AMGN: 149.59 (-0.31), KERX: 4.25 (+0.23), OMER: 12.66 (+0.58), KITE: 63.33 (+0.26), GILD: 100.65 (-0.16), MRK: 50.95 (-0.07), TEVA: 58.96 (-0.28)
Will Stem Cell Profits Measure Up?: NxR Biotechnologies' Alain Vertès
Life Sciences Report - Seeking Alpha - Thu Mar 19, 6:10AM CDT
It makes no sense to look at stem cell companies differently from drug or biologics companies. The technology may be different, but the diseases they seek to treat are the same. In fact, cell therapies may ultimately be more useful and more curative...
PFE: 33.24 (+0.15), ATHX: 1.14 (-0.01)
Chugai licenses ISPRI/OptiMatrix platform from EpiVax for de-risking biologics
PR Newswire - Thu Oct 30, 10:17AM CDT
Chugai Pharmaceutical Co., Ltd. (Chugai), signed an agreement with Rhode Island-based biotechnology company, EpiVax, Inc., to incorporate EpiVax's ISPRI immunogenicity screening and deimmunization technology into Chugai's drug development toolbox. Chugai is widely regarded as one of the most cutting edge biopharmaceutical companies in Japan. Researchers at Chugai will be utilizing the cloud-based in silico "Interactive Protein Screening and Reengineering Interface" (ISPRI) in conjunction with OptiMatrix, a tool for deimmunizing biologics, to screen and re-engineer therapeutic proteins for potential immunogenicity and deimmunize immune-dominant epitopes, known as clusters.
